BioMerieux PE Ratio 2017-2023 | BMXMF
Current and historical p/e ratio for BioMerieux (BMXMF) from 2017 to 2023. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. BioMerieux PE ratio as of November 05, 2024 is 0.00.
Please refer to the Stock Price Adjustment Guide for more information on our historical prices.
BioMerieux PE Ratio Historical Data | |||
---|---|---|---|
Date | Stock Price | TTM Net EPS | PE Ratio |
0.00 | nan |
Sector | Industry | Market Cap | Revenue |
---|---|---|---|
Medical | Medical Services | $13.601B | $3.977B |
bioM?rieux S.A. designs, develops, manufactures and markets systems in the field of vitro diagnostics. The company provides diagnostic solutions which determine the source of disease and contamination. It also offers solutions for managing infectious diseases, cancers and cardiovascular diseases in clinical applications. The company provides solutions for the enumeration of microbial flora, detection of specific pathogenic bacteria, monitoring of air and surface quality and sterility testing for the agri-food, cosmetics and pharmaceutical industries. bioM?rieux S.A. is based in Marcy L Etoile, France. |
Stock Name | Country | Market Cap | PE Ratio |
---|---|---|---|
Elevance Health (ELV) | United States | $96.890B | 12.02 |
Cencora (COR) | United States | $46.107B | 17.62 |
DiDi Global (DIDIY) | China | $23.233B | 0.00 |
ICON (ICLR) | Ireland | $18.679B | 16.64 |
Revvity (RVTY) | United States | $15.535B | 26.63 |
Avantor (AVTR) | United States | $15.498B | 23.24 |
Natera (NTRA) | United States | $15.385B | 0.00 |
Viatris (VTRS) | United States | $13.858B | 4.22 |
Solventum (SOLV) | United States | $12.636B | 0.00 |
CochLear (CHEOY) | Australia | $12.565B | 0.00 |
Medpace Holdings (MEDP) | United States | $10.202B | 28.74 |
Charles River Laboratories (CRL) | United States | $9.742B | 18.41 |
Sonic Healthcare (SKHHY) | Australia | $8.273B | 0.00 |
HealthEquity (HQY) | United States | $7.792B | 42.29 |
Doximity (DOCS) | United States | $7.787B | 49.34 |
Bausch + Lomb (BLCO) | Canada | $6.975B | 32.47 |
Life Times (LTH) | United States | $4.762B | 31.52 |
PACS (PACS) | United States | $4.502B | 0.00 |
Sotera Health (SHC) | United States | $4.367B | 23.36 |
Organon (OGN) | United States | $4.239B | 4.28 |
Surgery Partners (SGRY) | United States | $3.778B | 41.86 |
BrightSpring Health Services (BTSG) | United States | $3.070B | 65.30 |
Ardent Health Partners (ARDT) | United States | $2.577B | 0.00 |
Alignment Healthcare (ALHC) | United States | $2.546B | 0.00 |
Concentras Parent (CON) | United States | $2.480B | 0.00 |
Premier (PINC) | United States | $2.271B | 11.34 |
GoodRx Holdings (GDRX) | United States | $2.254B | 84.86 |
GeneDx Holdings (WGS) | United States | $2.057B | 0.00 |
Ryman Healthcare (RYHTY) | New Zealand | $2.036B | 0.00 |
Teladoc Health (TDOC) | United States | $1.575B | 0.00 |
AMN Healthcare Services Inc (AMN) | United States | $1.507B | 7.57 |
Progyny (PGNY) | United States | $1.425B | 25.06 |
Establishment Labs Holdings (ESTA) | $1.338B | 0.00 | |
Pediatrix Medical (MD) | United States | $1.319B | 12.91 |
CareDx (CDNA) | United States | $1.228B | 0.00 |
Agilon Health (AGL) | United States | $1.123B | 0.00 |
Embecta (EMBC) | United States | $0.864B | 5.76 |
InnovAge Holding (INNV) | United States | $0.822B | 0.00 |
QDM (QDMI) | Hong Kong, SAR China | $0.790B | 20.69 |
SBC Medicals (SBC) | United States | $0.722B | 0.00 |
Auna S.A (AUNA) | Luxembourg | $0.488B | 0.00 |
Sonida Senior Living (SNDA) | United States | $0.483B | 0.00 |
Enhabit (EHAB) | United States | $0.382B | 33.04 |
DocGo (DCGO) | United States | $0.355B | 13.35 |
COMPASS Pathways (CMPS) | United Kingdom | $0.309B | 0.00 |
Sera Prognostics (SERA) | United States | $0.255B | 0.00 |
ModivCare (MODV) | United States | $0.232B | 7.37 |
Beauty Health (SKIN) | United States | $0.211B | 0.00 |
Biodesix (BDSX) | United States | $0.195B | 0.00 |
LifeMD (LFMD) | United States | $0.192B | 0.00 |
Ascend Wellness Holdings (AAWH) | United States | $0.178B | 0.00 |
MultiPlan (MPLN) | United States | $0.136B | 0.00 |
Nutex Health (NUTX) | United States | $0.127B | 0.00 |
So-Young (SY) | China | $0.092B | 22.35 |
Harvard Apparatus Regenerative Technology (HRGN) | United States | $0.059B | 0.00 |
Singular Genomics Systems (OMIC) | United States | $0.057B | 0.00 |
OncoCyte (OCX) | United States | $0.049B | 0.00 |
NeueHealth (NEUE) | United States | $0.041B | 1.63 |
Co-Diagnostics (CODX) | United States | $0.039B | 0.00 |
IceCure Medical (ICCM) | Israel | $0.036B | 0.00 |
NeuroOne Medical Technologies (NMTC) | United States | $0.027B | 0.00 |
Pheton Holdings (PTHL) | China | $0.027B | 0.00 |
Oncology Institute (TOI) | United States | $0.021B | 0.00 |
SeaStar Medical Holding (ICU) | United States | $0.012B | 0.00 |
XWELL (XWEL) | United States | $0.009B | 0.00 |
Intelligent Bio Solutions (INBS) | United States | $0.007B | 0.00 |
BioNexus Gene Lab (BGLC) | $0.007B | 0.00 | |
KindlyMD (KDLY) | United States | $0.005B | 0.00 |
ISpecimen (ISPC) | United States | $0.004B | 0.00 |
NewGenIvf Group (NIVF) | Thailand | $0.003B | 0.00 |
Aclarion (ACON) | United States | $0.002B | 0.00 |
Cano Health (CANOQ) | United States | $0.001B | 0.00 |